دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Greetings from the editor 2023
Josef S Smolen
doi : 10.1136/ard-2022-223679
January 2023 - Volume 82 - 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L Hyrich, Janet E Pope, Savia de Souza, Tanja A Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P M Vliet Vlieland, René Westhovens, Désirée van der Heijde
doi : 10.1136/ard-2022-223356
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B M Landewé, Filip E Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A van Gaalen, Pál Géher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina López-Medina, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compán, Michael J Nissen, Fernando M Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziade, Désirée van der Heijde
doi : 10.1136/ard-2022-223296
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA).
EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021
Marc H A Jansen, Christien Rondaan, Geertje E Legger, Kirsten Minden, Yosef Uziel, Natasa Toplak, Despoina Maritsi, Lotte van den Berg, Guy A M Berbers, Patricia Bruijning, Yona Egert, Christophe Normand, Marc Bijl, Helen E Foster, Isabelle Koné-Paut, Carine Wouters, Angelo Ravelli, Ori Elkayam, Nicolaas M Wulffraat, Marloes W Heijstek
doi : 10.1136/annrheumdis-2022-222574
Objectives Recent insights supporting the safety of live-attenuated vaccines and novel studies on the immunogenicity of vaccinations in the era of biological disease-modifying antirheumatic drugs in paediatric patients with autoimmune/inflammatory rheumatic diseases (pedAIIRD) necessitated updating the EULAR recommendations.
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases
James M Gwinnutt, Maud Wieczorek, Andra Balanescu, Heike A Bischoff-Ferrari, Annelies Boonen, Giulio Cavalli, Savia de Souza, Annette de Thurah, Thomas E Dorner, Rikke Helene Moe, Polina Putrik, Javier RodrÃguez-Carrio, LucÃa Silva-Fernández, Tanja Stamm, Karen Walker-Bone, Joep Welling, Mirjana I Zlatković-Å venda, Francis Guillemin, Suzanne M M Verstappen
doi : 10.1136/annrheumdis-2021-222020
Objectives A European League Against Rheumatism taskforce was convened to review the literature and develop recommendations on lifestyle behaviours for rheumatic and musculoskeletal diseases (RMDs).
2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work
Annelies Boonen, Casper Webers, Maarten Butink, Birgit Barten, Neil Betteridge, Dame Carol Black, Ann Bremander, Boryana Boteva, Olga Brzezińska, Lina Chauhan, Sarah Copsey, Vera Guimarães, Monique Gignac, Jennifer Glaysher, Frans Green, Jan L Hoving, Mary Lucy Marques, Hana Smucrova, Tanja A Stamm, Dieter Wiek, Ross Wilkie, Anthony D Woolf, Gerd R Burmester, Johannes W Bijlsma, Suzanne M M Verstappen
doi : 10.1136/ard-2022-222678
Aim As part of its strategic objectives for 2023, EULAR aims to improve the work participation of people with rheumatic and musculoskeletal diseases (RMDs). One strategic initiative focused on the development of overarching points to consider (PtC) to support people with RMDs in healthy and sustainable paid work participation.
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Charlotte LM Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa, Peter Böhm, Sasa Cucnik, Ori Elkayam, Guro L Goll, Femke Hooijberg, Meghna Jani, Patrick DW Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compán, Katherine Payne, Martin E Perry, Chamaida Plasencia-Rodriguez, Simon R Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M Ward, Gertjan Wolbink, John D Isaacs
doi : 10.1136/annrheumdis-2022-222155
Objective To develop EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs).
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A Stamm, Farideh Alasti, Diane Lacaille, Josef S Smolen, David T Felson
doi : 10.1136/ard-2022-223413
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the two sets of criteria, our goals were to externally validate a revision of the Boolean remission criteria using a higher PtGA threshold and to validate the provisionally endorsed index-based criteria.
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Désirée van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja A Stamm, Jan W Schoones, Josef S Smolen, Robert B M Landewé
doi : 10.1136/ard-2022-223358
This systematic literature review (SLR) regarding the efficacy, duration of use and safety of glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja A Stamm, Jan W Schoones, Robert B M Landewé
doi : 10.1136/ard-2022-223365
Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA).
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Stamm, Jan W Schoones, Robert B M Landewé
doi : 10.1136/ard-2022-223357
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A Connell, Zoltan Szekanecz
doi : 10.1136/ard-2022-222259
Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance.
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B M Landewé, Sofia Ramiro, Désirée van der Heijde, Elena Nikiphorou
doi : 10.1136/ard-2022-223298
Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA.
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
Augusta Ortolan, Casper Webers, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert BM Landewé, Sofia Ramiro, Désirée van der Heijde, Elena Nikiphorou
doi : 10.1136/ard-2022-223297
Objective To update the evidence of non-biological treatments for axial spondyloarthritis (axSpA), as a basis for the 2022 Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA.
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
Hermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, Nuray Aktay Ayaz, Inmaculada Calvo Penades, Ozgur Kasapcopur, Vyacheslav G Chasnyk, Markus Hufnagel, Zbigniew Żuber, Grant Schulert, Seza Ozen, Adelina Rakhimyanova, Athimalaipet Ramanan, Christiaan Scott, Betul Sozeri, Elena Zholobova, Ruvie Martin, Xuan Zhu, Sarah Whelan, Luminita Pricop, Alberto Martini, Daniel Lovell, Nicolino Ruperto
doi : 10.1136/ard-2022-222849
Background Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.
Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’
Hendrik Schulze-Koops, Alla Skapenko, Andreas Krause, Klaus Krueger, Hanns-Martin Lorenz, Philipp Sewerin, Christof Specker, Ulf G Wagner, Anna Voormann, Ulf Mueller-Ladner, Reinhard E Voll
Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Schulze-Koops et al
Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid GarcÃa, Jose Ignacio Colomer, Juan A Jover, BenjamÃn Fernandez-Gutierrez, Lydia Abasolo
Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study
Sergey Moiseev, Sergey Avdeev, Ekaterina Tao, Michail Brovko, Nikolay Bulanov, Anastasiia Zykova, Larisa Akulkina, Irina Smirnova, Victor Fomin
Response to ‘Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study’ by Moiseev et al
Sofia Ramiro, Robert B M Landewé, Rémy Mostard
Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’
Elisa Gremese, Giovanni Brondani, Luca Apollonio, Gianfranco Ferraccioli
Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Gremese et al
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Correspondence on ‘Gender disparity in authorship of guidelines and recommendations in rheumatology’
Sarah Stewart, Elizaveta Rakhmanova, Nicola Dalbeth
Response to: ‘Correspondence on ‘Gender disparity in authorship of guidelines and recommendations in rheumatology’’ by Stewart et al
Giovanni Adami, Camilla Benini, Elisabetta Vantaggiato, Denise Rotta, Ombretta Viapiana, Davide Gatti, Maurizio Rossini, Annamaria Iagnocco
Correspondence on ‘Tapering towards DMARD-free remission in rheumatoid arthritis’
Iveth Eunice GarcÃa, Carlos Abud-Mendoza
Response to: ‘Correspondence on ‘Tapering towards DMARD-free remission in rheumatoid arthritis’ by Garcia et al
Elise van Mulligen, Pascal Hendrik Pieter de Jong
Correspondence on ‘Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease’
Gwo-Ping Jong, Lung-Fa Pan, Tsung-Kun Lin, Hung-Yi Chen
Response to ‘Correspondence on ‘Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease� by Jong et al
Brian Bridal Løgstrup, Kevin Kris Warnakula Olesen, Dzenan Masic, Christine Gyldenkerne, Pernille Gro Thrane, Torkell Ellingsen, Hans Erik Bøtker, Michael Maeng
Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’
Ran Cui, Qiang Tong, Zhi-Yong Chen, Miao Chen, Sheng-Ming Dai
Response to: ‘Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’’ by Cui et al
Ke-Qi Liu, Jiangwei Xia, Qiu-Ping Chen, Jian-Qiang Yang, Hou-Feng Zheng
Correspondence on ‘Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities’
Johan Rönnelid, Örjan Dahlström, Charlotte Dahle, Christopher Sjöwall
Response to: ‘Correspondence on ‘Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities’’ by Rönnelid et al
Sindhu R Johnson, Martin Aringer
Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia’
Hong Huang, Zhuoli Zhang
Response to: ‘Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia’’ by Huang and Zhang
Han-You Mo, James Cheng Chung Wei, Xiao-Huan Chen, Hsin-Hua Chen
Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia: a nationwide population-based cohort study’
George N Goulielmos, Maria I Zervou
Response to: ‘Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia: a nationwide population-based cohort study’’ by Goulielmos and Zervou
Han-You Mo, Xiao-Huan Chen, James Cheng Chung Wei, Hsin-Hua Chen
Correspondence on ‘Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement’
Mirko Manetti
Response to: ‘Correspondence on ‘Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement’’ by Manetti
Kimberly Showalter, Cynthia Magro, Yaxia Zhang, Robert Spiera, Dana E Orange, Jessica K Gordon
Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’
Akshay Parikh, Phani Kumar Devarasetti, Liza Rajasekhar
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al
Rona M Smith, Peter A Merkel, David Jayne
Case of adult large vessel vasculitis after SARS-CoV-2 infection
Ryohei Oda, Takeshi Inagaki, Masahiro Ishikane, Masatoshi Hotta, Akira Shimomura, Mitsuhiro Sato, Takato Nakamoto, Yutaro Akiyama, Kei Yamamoto, Ryogo Minamimoto, Hiroshi Kaneko, Norio Ohmagari
Analysis on misdiagnosis of a case of novel variant of NLRP12
Xiran Yang, Bo Zhao, Yabin Liao
COP27 climate change conference: urgent action needed for Africa and the world
Chris Zielinski
doi : 10.1136/ard-2022-223475
